FOR HEALTHCARE PROFESSIONALS
Precision oncology navigation that extends your team's reach - not your workload.
Navexio identifies missed molecular and genomic diagnostic opportunities, coordinates advanced testing, and navigates clinical trial and drug access pathways — supporting your clinical decision-making with structured, evidence-based insights.
Metastatic TNBC
FGFR2 Amplification Identified After Multiple Lines of Therapy — No Prior Biomarker Testing Performed
A 63-year-old patient with metastatic triple-negative breast cancer had progressed through chemotherapy, immunotherapy, and antibody-drug conjugates. Navexio discovered that no biomarker testing had been performed and coordinated comprehensive molecular profiling, identifying an FGFR2 amplification. This enabled a transition from non-targeted therapies to a biomarker-driven treatment strategy with access to FGFR2-targeted therapy.
Outcome: Biomarker-driven strategy replaced exhausted standard options → targeted therapy access pathway opened.
Stage IV GEJ Adenocarcinoma
HER2 Status Resolved Through Coordinated Re-Testing After Inconclusive Hospital Assays
A 75-year-old patient with metastatic gastroesophageal junction adenocarcinoma had equivocal IHC and negative FISH results due to poor sample quality. Navexio coordinated tissue and liquid biopsy re-testing, revealing HER2 overexpression (IHC 3+) and RNA overexpression (ERBB2/ERBB3), enabling a shift to HER2-targeted therapy including trastuzumab and trastuzumab deruxtecan.
Outcome: Outcome: Inconclusive biomarker resolved → treatment shifted to HER2-targeted approach.
HOW NAVEXIO SUPPORTS YOUR PRACTICE
Five services designed to reduce your administrative burden
Each service offloads operational complexity from the care team while delivering structured, evidence-based outputs for clinical discussion.
Molecular & Genomic Review
Comprehensive audit of prior testing (IHC, PCR, NGS, ctDNA) to identify missing, incomplete, or suboptimal biomarker assessments, including evaluation of panel selection and testing methodology.
For HCPs: Saves time on detailed retrospective chart and biomarker review, and helps ensure no clinically relevant molecular insight is overlooked without requiring additional effort from the treating team.
Diagnostic Navigation
Coordination of advanced molecular testing, including tissue retrieval, sample logistics, and identification of best-fit laboratories and sequencing platforms (DNA vs RNA, panel selection).
For HCPs: Offloads the operational and administrative complexity of ordering and coordinating advanced diagnostics, reducing back-and-forth with pathology departments and external labs.
Interpretation & Clinical Context
Structured review of molecular profiling results with synthesis of relevant evidence from peer-reviewed literature, clinical guidelines (NCCN, ESMO, ASCO), and emerging data — including associations with targeted therapies, resistance mechanisms, and prognostic insights.
For HCPs: Provides a consolidated, evidence-based summary of complex molecular findings, reducing the time required to review literature and supporting efficient clinical interpretation by the treating team.
Clinical Trial & Drug Access
Identification and prioritization of biomarker-driven clinical trials, evaluation of drug access pathways (on-label, off-label, compassionate use, cross-border options), and coordination with external trial sites including eligibility clarification and logistics.
For HCPs: Reduces administrative burden of identifying and coordinating clinical trial opportunities, allowing the care team to focus on clinical decision-making while patients are connected to appropriate pathways.
Oncology Nurse Navigation
Dedicated oncology nurse support for patient education, care coordination, and ongoing guidance throughout the treatment journey.
For HCPs: Reduces inbound patient questions and coordination demands on clinic staff, while reinforcing physician-directed care plans and improving patient preparedness.
SCIENTIFIC APPROACH
Evidence-based, guideline-referenced, clinically contextualized
Navexio synthesizes molecular diagnostics, peer-reviewed literature, and real-world access pathways — leveraging deep expertise in cancer biology and genomics to ensure each case is explored with scientific rigor.
Sources & References
Peer-reviewed scientific literature
International clinical guidelines (NCCN, ESMO, ASCO)
Clinical trial databases and emerging translational data
Recognized actionability frameworks (AMP/ASCO/CAP, ESCAT)
Diagnostic Review Scope
Genomic alterations (SNVs, CNVs, gene fusions)
Testing methodology assessment (DNA vs RNA sequencing)
Tumor biology, heterogeneity, and resistance mechanisms
Biomarker contextualization for targeted therapy alignment
REFERRAL
Simple referral. No administrative burden on your team.
Patients may be referred directly by their physician or may self-refer. Navexio manages all coordination, and all engagements are conducted with appropriate patient consent. Outputs are structured to support efficient discussion with the treating team.
When to Consider Navexio
Patient has progressed through multiple lines of therapy without comprehensive molecular profiling
Prior biomarker testing was inconclusive, incomplete, or limited to small panels
Complex case where additional evidence synthesis could support treatment planning
Patient seeking clinical trial options or access to therapies outside standard pathways
Patient or family requesting additional diagnostic clarity and navigation support